CodeBreaK 200 — Sotorasib versus Docetaxel in Previously Treated KRAS G12C-Mutated NSCLC

Phase 3 · 2023 · Non-Small Cell Lung Cancer

Design

Randomized sotorasib versus docetaxel after prior platinum chemotherapy and immunotherapy.

Population

Previously treated advanced KRAS G12C-mutated NSCLC.

Primary Endpoint

progression-free survival (PFS)

Key Result

Sotorasib significantly improved PFS versus docetaxel (median 5.6 vs 4.5 mo; HR 0.66) with a more favorable toxicity profile.

Guideline Impact

Second-line KRAS G12C-mutated advanced NSCLC